178 results about "Ischemic brain injury" patented technology

A method of reducing oxidative stress in the brain of an organism having a blood brain barrier and suffering an ischemic brain injury, the method comprising the step of administering a compound to the organism, the compound having (a) a combination of molecular weight and membrane miscibility properties for permitting the compound to cross the blood brain barrier of the organism; (b) a readily oxidizable chemical group for exerting antioxidation properties; and (c) a chemical make-up for permitting the compound or its intracellular derivative to accumulate within the cytoplasm of cells.

The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.

An alkyl ether derivative represented by the formula:

wherein R¹, R², R³, R⁴, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

The invention relates to a target spot and a medicine for treating cerebral injury, in particular to a material used for maintaining TRPC6 (Transient Receptor Potential-canonical Channel) level to prevent or treat hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration, and application thereof in preparation of a medicine or medicine composition for preventing or treating the hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration. The invention also relates to a method for screening materials capable of being used for treating or preventing injury caused by ischemia.

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.

The invention relates to the field of Chinese medicaments, in particular to a Chinese medicinal composition for preventing and treating ischemic brain injury, and a preparation method thereof. The Chinese medicinal composition for preventing and treating ischemic brain injury is an orally taken preparation prepared from extracts of raw astragalus roots, panax notoginseng, kudzuvine roots, baikal skullcap roots and gardenia serving as main active components, as well as pharmaceutical auxiliary materials. The preparation has obvious therapeutic effects on cerebral infarction convalescent symptoms of which the clinical manifestations are eye-mouth distortion, glossolalia, slobbering or hemiplegia, dark red tongue or yellow greasy tongue coating, weak or uneven pulse and the like.

The present invention relates to a carthamus yellow richly containing carthamus yellow B, in which the carthamus yellow B content is greater than or equal to 80% and less than 100%, the optimized content is greater than or equal to 90% or less than 100%. Said invention also relates to its preparation method and medicine composition containing said carthamus yellow. Said invention also provides its application in preparation of medicine for preventing and curing ischemic brain injury.

The invention discloses a structural general formula of a compound LQC-T and the synthesis and the application of the compound LQC-T. Pharmacological experiments prove that the compound has an obvious effect of promoting new vessels of chick chorioallantoic membranes to grow; a compound LQC-T4 has an obvious medicinal effect of treating ischemic brain injury stroke and the sequela of the ischemic brain injury stroke; the maximal LQC-T4 single-day dose of mice is 5,400mg/kg; and the compound is extremely high in safety and can be used for preparing a medicine for treating the ischemic brain injury stroke and the sequela of the ischemic brain injury stroke after toxic responses do not occur after continuous observation within 1 to 4 days. According to the structural formula of the compound LQC-T, R is protocatechuic acid, protocatechuic aldehyde, vanillic acid, gallic acid, caffeic acid, ferulic acid and other aromatic organic acids or phenols or structural analogues of the organic acids or phenols.

The invention relates to the field of medicine synthesis, and discloses a PSD-95 inhibitor. The PSD-95 inhibitor disclosed by the invention is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is used for preparing neuroprotective drugs after ischemic brain injury.

The invention discloses a small peptide TAT-AVPY for treating ischemic brain damage, and an application thereof. The complete sequence of the small peptide TAT-AVPY is H-YGRKKRRQRRR-AVPY-OH, represented by SEQ ID NO:1. With the small peptide TAT-AVPY provided by the invention, the binding of XIAP and proaspase-9 (Casp 9) can be reduced; nitrosylation of XIAP and proaspase-9 (Casp 9) can be alleviated; and proaspase-9 activation can be alleviated. Therefore, cell apoptosis induced by cerebral ischemia can be alleviated. Also, TAT can directly bring fused small peptide into cells, such that a problem of the approach for the drug to enter cells is solved, and medication is convenient. The small peptide TAT-AVPY has no immunogenicity, and does not cause an immune response of a body. Therefore, side effects are reduced, and the effectiveness of secondary medication or more is ensured.

This invention relates to the use of kauranes compounds having the structure of formula (I) in the manufacture of a medicament for treating and preventing the diseases such as coronary heart disease, cerebral apoplexy, cerebral ischemia and rhythm disturbance etc. The present compounds also have obvious protective effect against cerebral infarction and cerebral injure from ischemia, in which: R¹ is H, hydroxy or alkoxy; R² is carboxy, carboxylate group, acyl halide, aldehyde group, hydroxymethyl, ester group which can be hydrolyzed to carboxy, amide, acyl or ether group; R³, R⁴, R⁵, R⁶, R⁸ each independently are H, hydroxy, hydroxymethyl, ester group which can be hydrolyzed to hydroxymethyl, or alkoxymethyl; R⁷ is methyl, hydroxymethyl, ester group which can be hydrolyzed to hydroxymethyl, or alkoxymethyl; R⁹ is methylene or oxygen atom.

The invention discloses application of (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone in preparing a medicine for treating cerebrovascular diseases. The related research indicates that the compound has an obvious cranial nerve protection effect, obviously reduces the focal cerebral ischemia rat cerebral infarction volume and remarkably improves the neurologic symptom. The (E)-2-(3,5-dimethoxybenzylidene)-cyclopentanone is used for preventing or treating the diseases such as ischemic brain injury, cerebral hemorrhage, cerebral thrombosis, cerebral embolism, cerebral infarction, cerebral apoplexy, lacunar infarction, transient ischemic attack, cerebral arteriosclerosis, diabetic cerebrovascular complications and the like.

The invention relates to application of genipin in prevention or treatment of ischemic brain injury. Brain injury is particularly related to injury of microglial cells or human umbilical vein endothelial cells. The invention further relates to a medicine composition containing genipin for preventing or treating ischemic brain injury.

Belonging to the pharmaceutical field, the invention relates to application of nicotinamide phosphoribosyltransferase (NAMPT) in preparation of neuroprotective and rehabilitation drugs. Experiments of the invention show that NAMPT recombinant protein can penetrate the blood-brain barrier to significantly reduce the volume of ischemic brain injury and alleviate white matter injury after ischemic brain injury; the NAMPT recombinant protein can significantly improve long-term behaviors after ischemic brain injury; the NAMPT recombinant protein can raise revascularization related factors to enhance revascularization after brain hypoxia and neuron regeneration after brain hypoxia, and promote post-injury neurologic function reestablishment; and by mediating oligodendrocyte regeneration and alleviating the demyelination effect of local lysolecithin, the NAMPT recombinant protein can promote restoration of white matter after injury and strengthen post-injury neurologic function reestablishment. Results show that the NAMPT recombinant protein plays a long-term neuroprotective role in drugs treating cerebral stroke, traumatic brain injury and multiple sclerosis, and can be used as a neuroprotective drug to treat acute and chronic injury caused by brain stroke.

The invention discloses a jasminoidin or gardenia total iridoid glycoside liposome preparation which comprises liposome formed by phospholipid and cholesterol, and asminoidin or gardenia total iridoid glycoside wrapped and loaded in the liposome, wherein the weight ratio of phospholipid to cholesterol is (3:1)-(7:1), preferably 5:1; the weight ratio of asminoidin or gardenia total iridoid glycoside to phospholipid is (1:2)-(1:8), preferably 1:4; and the phospholipid is selected from lecithin, soya lecithin, yolk phospholipid or phosphatidylcholine, preferably soya lecithin or yolk phospholipid. The preparation provided by the invention has the advantages that the contact time of the asminoidin or gardenia total iridoid glycoside and mucosa is prolonged. The liposome preparation can be prepared into a spraying agent after being loaded into a nasal suction apparatus, and is applied in a nasal delivery mode, so that the distribution of the asminoidin or gardenia total iridoid glycoside in brain tissues is effectively improved. The invention also discloses the application of the liposome preparation in preparation of medicaments for treating hypoxic ischemic brain damage diseases.

The invention discloses a carbonic oxide inhalator which comprises a control part, a measuring circuit part and a CO-air mixing device. The CO-air mixing device is provided with a CO inlet, an air inlet and a mixed gas outlet. The control part comprises a computer and a displayer. The measuring circuit part comprises a pressure sensor, a current amplifier, a filter and an A/D convertor, wherein the pressure sensor measures the gas pressure of input CO gas, air and mixed gas, current amplification and filtering are conducted on the gas pressure through the current amplifier and the filter respectively, then the gas pressure is converted into a digital signal through the A/D convertor and is input into the computer, and the computer analyzes data of the measuring circuit part and outputs a control command. The carbonic oxide inhalator is used for treating diseases such as pulmonary arterial hypertension, ARDS, respiratory failure caused by acute lung injury, hypoxic ischemic brain damage and shock.